logo

For the Inventor, By the Inventor

Hwaseong, South Korea

Hanmi Science Co., Ltd.

USPTO Granted Patents = 63

% Expired Patents = 30.2



Trademarks = 3

Forward Citations = 178

Loading Chart...
Loading Chart...

144 inventors (with patents filed for the assignee):

goldMedal Se Chang Kwon (41 out of 90 patents)

silverMedal Sung Youb Jung (23 out of 63 patents)

bronzeMedal Gwan Sun Lee (21 out of 44 patents)

4.  Sung Min Bae (11 out of 31 patents)

5.  Young Jin Park (10 out of 89 patents)

6.  Dae Hae Song (10 out of 15 patents)

7.  Dae Jin Kim (10 out of 34 patents)

8.  Maeng Sup Kim (9 out of 14 patents)

9.  Myung Hyun Jang (8 out of 15 patents)

10.  In Young Choi (8 out of 31 patents)

11.  Sung H Hong (8 out of 106 patents)

12.  Dae Seong Im (6 out of 6 patents)

13.  Jin Sun Kim (6 out of 10 patents)

14.  Young Kyung Park (6 out of 6 patents)

15.  Jae Hee Shin (6 out of 6 patents)


Core Competencies:
Polypeptide
Conjugate
Oxyntomodulin
Insulin
Immunoglobulin Fragment
Long-Acting
Pharmaceutical Composition
Obesity Treatment
G-CSF
Protein Kinase
Erythropoietin
Diabetes

63 patents:

1. 11872283 - Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (2024-01-16),
2. 11434271 - Method for preparing physiologically active polypeptide complex (2022-09-06),
3. 11168109 - Process for preparation of physiologically active polypeptide complex (2021-11-09),
4. 11058776 - IgG Fc fragment for a drug carrier and method for the preparation thereof (2021-07-13),
5. 11040110 - Polypeptide complex comprising non-peptidyl polymer having three functional ends (2021-06-22),
6. 10744187 - Insulin conjugate using an immunoglobulin fragment (2020-08-18),
7. 10442848 - Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same (2019-10-15),
8. 10363320 - Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (2019-07-30),
9. 10272159 - IgG Fc fragment for a drug carrier and method for the preparation thereof (2019-04-30),
10. 10251957 - Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate (2019-04-09),
11. 10112954 - Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase (2018-10-30),
12. 10071171 - Polypeptide complex comprising non-peptidyl polymer having three functional ends (2018-09-11),
13. 10071166 - Protein complex using an immunoglobulin fragment and method for the preparation thereof (2018-09-11),
14. 10064951 - Liquid formulation of highly concentrated long-acting human growth hormone conjugate (2018-09-04),
15. 9981017 - Insulin conjugate using an immunoglobulin fragment (2018-05-29),
Company Overview
Hanmi Science Co., Ltd., headquartered in Hwaseong, South Korea, specializes in the development and manufacturing of innovative polypeptide conjugates. The company focuses on advanced pharmaceutical compositions, particularly in the realm of obesity treatment. Its core technologies include oxyntomodulin, insulin, and immunoglobulin fragments, emphasizing long-acting formulations. Hanmi Science is dedicated to addressing significant health challenges through its cutting-edge research in biopharmaceuticals and therapeutic solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

63 Patents

#4 in Hwaseong

#270 in South Korea

#11,640 in the World

Hwaseong, KR
Hwaseong, South Korea

Hanmi Science Co., Ltd.

Forward Citations = 178

144 inventors:

goldMedal Se Chang Kwon (41 out of 90 patents)

silverMedal Sung Youb Jung (23 out of 63 patents)

bronzeMedal Gwan Sun Lee (21 out of 44 patents)

4.  Sung Min Bae (11 out of 31 patents)

5.  Young Jin Park (10 out of 89 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hanmi Science Co., Ltd.. Retrieved from https://idiyas.com/company/hanmi-science-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…